請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68028
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡丰喬(Feng-Chiao Tsai) | |
dc.contributor.author | Jian-Wei Wu | en |
dc.contributor.author | 吳建緯 | zh_TW |
dc.date.accessioned | 2021-06-17T02:11:28Z | - |
dc.date.available | 2025-08-17 | |
dc.date.copyright | 2020-09-01 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-17 | |
dc.identifier.citation | 1. Chow, L.Q.M., Head and Neck Cancer. N Engl J Med, 2020. 382(1): p. 60-72. 2. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424. 3. Global Burden of Disease Cancer, C., et al., Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol, 2017. 3(4): p. 524-548. 4. Warnakulasuriya, S., C. Trivedy, and T.J. Peters, Areca nut use: an independent risk factor for oral cancer. BMJ, 2002. 324(7341): p. 799-800. 5. Chaturvedi, A.K., et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol, 2011. 29(32): p. 4294-301. 6. Pignon, J.P., et al., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol, 2009. 92(1): p. 4-14. 7. Vermorken, J.B., et al., Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer, 2008. 112(12): p. 2710-9. 8. Maltoni, M. and D. Amadori, Prognosis in advanced cancer. Hematol Oncol Clin North Am, 2002. 16(3): p. 715-29. 9. Argiris, A., et al., Head and neck cancer. Lancet, 2008. 371(9625): p. 1695-709. 10. Itoh, N. and D.M. Ornitz, Evolution of the Fgf and Fgfr gene families. Trends Genet, 2004. 20(11): p. 563-9. 11. Freier, K., et al., Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol, 2007. 43(1): p. 60-6. 12. Henson, B.J. and S.M. Gollin, Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet Genome Res, 2010. 128(4): p. 192-8. 13. Marshall, M.E., et al., Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res, 2011. 17(15): p. 5016-25. 14. Koole, K., et al., Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med, 2016. 5(2): p. 275-84. 15. Vairaktaris, E., et al., FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Anticancer Res, 2006. 26(6B): p. 4217-21. 16. Sweeny, L., et al., Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor. Laryngoscope, 2012. 122(7): p. 1539-44. 17. Gyanchandani, R., et al., A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol Cancer Res, 2013. 11(12): p. 1585-96. 18. Ornitz, D.M., FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays, 2000. 22(2): p. 108-12. 19. Miki, T., et al., Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A, 1992. 89(1): p. 246-50. 20. Chaffer, C.L., et al., Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res, 2006. 66(23): p. 11271-8. 21. Sonvilla, G., et al., Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer, 2010. 102(7): p. 1145-56. 22. Ornitz, D.M. and N. Itoh, The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol, 2015. 4(3): p. 215-66. 23. Naski, M.C., et al., Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet, 1996. 13(2): p. 233-7. 24. Foldynova-Trantirkova, S., W.R. Wilcox, and P. Krejci, Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat, 2012. 33(1): p. 29-41. 25. Turner, N. and R. Grose, Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer, 2010. 10(2): p. 116-29. 26. Kelleher, F.C., et al., Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis, 2013. 34(10): p. 2198-205. 27. Goetz, R. and M. Mohammadi, Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol, 2013. 14(3): p. 166-80. 28. Kouhara, H., et al., A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell, 1997. 89(5): p. 693-702. 29. Xu, H., K.W. Lee, and M. Goldfarb, Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins. J Biol Chem, 1998. 273(29): p. 17987-90. 30. Olayioye, M.A., et al., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000. 19(13): p. 3159-67. 31. Bellot, F., et al., Ligand-induced transphosphorylation between different FGF receptors. EMBO J, 1991. 10(10): p. 2849-2854. 32. Ueno, H., et al., A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J Biol Chem, 1992. 267(3): p. 1470-6. 33. Del Piccolo, N., S. Sarabipour, and K. Hristova, A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. J Biol Chem, 2017. 292(4): p. 1288-1301. 34. Kuo, G.-H., Fibroblast growth factor receptor 3 affects cell migration and cancer progression in head and neck squamous cell carcinoma, in Department and Graduate Institute of Pharmacology. 2016, National Taiwan University. p. 1-61. 35. Cha, J.Y., et al., Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res, 2008. 6(3): p. 435-45. 36. Fletcher, M.N., et al., Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun, 2013. 4: p. 2464. 37. Matsuda, Y., J. Ueda, and T. Ishiwata, Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Patholog Res Int, 2012. 2012: p. 574768. 38. Chang, L.-Y., Signaling interaction between FGFR and EGFR in HNSCC: focusing on cell migration, in Department and Graduate Institute of Pharmacology. 2018, National Taiwan University. p. 1-80. 39. Chu, C.-Y., Signalling interactions between FGFR and EGFR alter the migration of head and neck cancer cells, in Department and Graduate Institute of Pharmacology. 2019, National Taiwan University. p. 1-122. 40. Hsiao, P.-C., Quantitative studies of fibroblast growth factor interactions in HNSCC cell migration, in Department and Graduate Institute of Pharmacology. 2019, National Taiwan University. p. 1-69. 41. Bossi, P., et al., Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget, 2016. 7(45): p. 74362-74379. 42. Byeon, H.K., M. Ku, and J. Yang, Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp Mol Med, 2019. 51(1): p. 1-14. 43. Liu, X., et al., The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. J Exp Clin Cancer Res, 2019. 38(1): p. 219. 44. Tokunaga, R., et al., Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget, 2016. 7(15): p. 19748-61. 45. Berti, D.A. and R. Seger, The Nuclear Translocation of ERK. Methods Mol Biol, 2017. 1487: p. 175-194. 46. Zhang, X., et al., Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem, 2006. 281(23): p. 15694-700. 47. Webster, M.K. and D.J. Donoghue, Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol, 1997. 17(10): p. 5739-47. 48. Jang, J.H., Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. Biochem Biophys Res Commun, 2002. 292(2): p. 378-82. 49. Terada, M., et al., Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol Cell Biol Res Commun, 2001. 4(6): p. 365-73. 50. Garcia, S., et al., Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci Transl Med, 2013. 5(203): p. 203ra124. 51. Farrell, B. and A.L. Breeze, Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem Soc Trans, 2018. 46(6): p. 1753-1770. 52. Sarabipour, S. and K. Hristova, Mechanism of FGF receptor dimerization and activation. Nat Commun, 2016. 7: p. 10262. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68028 | - |
dc.description.abstract | 纖維母細胞生長因子受器(Fibroblast growth factor receptor, FGFR)是種在細胞遷移上扮演著重要角色的膜蛋白,FGFR家族有著不同的成員(FGFR1-4)與亞型(Isoform IIIb IIIc)。其活化方式是同成員的FGFR結合形成FGFR homodimer,並促使下游訊息傳遞,而也有文獻指出不同成員的FGFR能結合形成FGFR heterodimer,但對於FGFR heterodimer的功能目前仍是未知。 頭頸部鱗狀上皮細胞癌是種高致死率且容易發生轉移的癌症,許多研究指出FGFR的功能異常與頭頸癌之間有高度相關的關係,然而目前卻沒有以FGFR作為標靶的治療藥物,為了探索FGFR如何調控頭頸癌細胞的遷移,我們進行傷口癒合實驗(Wound healing assay),發現過度表達FGFR3IIIb會降低細胞遷移的速度,此外頭頸癌細胞是種表現FGFR2為主的細胞株,基於以上的結果,我們推測過度表達的FGFR3或許能與FGFR2結合形成FGFR2-3 heterodimer,並抑制FGFR2活化所產生的訊息傳遞。 為了驗證假說,我們以生物物理光學技術(Fluorescence cross-correlation spectroscopy, FCCS)以及生物化學技術(Co-immunoprecipitation, Co-IP)證實FGFR2-3 heterodimer的存在。為了進一步了解FGFR2-3 heterodimer的功能,讓表現FGFR2為主的頭頸癌細胞過度表達FGFR3來形成FGFR2-3 heterodimer,再藉由FGF7的刺激來觀察FGFR2-3 heterodimer在MAPK、AKT、STAT pathway上的影響。免疫螢光染色(Immunofluorescence, IF)結果顯示FGFR2-3 heterodimer不會啟動MAPK pathway,而西方墨點法(Western blot, WB)顯示FGFR2-3 heterodimer不會啟動AKT pathway,因此初步結果指出FGFR2-3 heterodimer會干擾MAPK與AKT pathway的訊息傳遞。 為了更進一步探討FGFR2-3 heterodimer對下游訊息傳遞的影響,我造了點突變(K508R)、失去膜內區域(∆Intra)與失去穿膜區域(∆Trans)的FGFR3質體(FGFR3 mutants),文獻指出K508R點突變會使FGFR3失去活性,缺少膜內區域的FGFR3-∆Intra也沒有活性,而FGFR3-K508R與FGFR3-∆Intra保留穿膜區域,預期會留在膜上與FGFR2形成Heterodimer來干擾訊息傳遞,因此我們將FGFR3-K508R與FGFR3-∆Intra作為負向對照組;而文獻指出失去穿膜區域會使FGFR3被分泌到細胞外,但細胞外的FGFR3-∆Trans是否能與膜上的FGFR2形成Heterodimer來抑制FGFR2的訊息傳遞仍是未知,因此想探索FGFR3-∆Trans作為調控FGFR2活性蛋白藥物的可能性,而膜質分離的結果顯示所有FGFR3 mutants都位於膜上,推測FGFR3-∆Trans能與其他FGFR形成Heterodimer而留在膜上,期望能透過FGFR3-K508R與FGFR3-∆Intra來解開FGFR2-3 heterodimer的功能以及透過FGFR3-∆Trans找出對付頭頸癌或FGFR2相關疾病的對策。 | zh_TW |
dc.description.abstract | Fibroblast growth factor receptor (FGFR), a kind of receptor tyrosine kinase (RTK) with 4 members (FGFR1-4) and two isoforms (IIIb IIIc), plays an important role in cellular migration. It is well-known that FGFRs of same member will form homodimer to trigger downstream signal transduction; however, some reports also indicated that different FGFRs would form heterodimer. So far, the function of FGFR2-3 heterodimer still remains unclear. Head and neck squamous cell carcinoma (HNSCC) is a kind of cancer with high mortality and high metastasis. Many reports pointed out that aberrant FGFR signaling is highly correlated with HNSCC. However, there is still no effective treatment targeting FGFR. To explore how FGFR regulates HNSCC migration, we conducted wound healing assay and found that overexpression of FGFR3IIIb would decrease migration speed of SAS cells, one of HNSCC cell lines. Besides, we confirmed that SAS is a FGFR2-dominant cell line with lower expression of FGFR3. Based on these evidence, we inferred that FGFR3 may bind with FGFR2 to form FGFR2-3 heterodimer and the function of FGFR2-3 heterodimer is to block signal transduction of FGFR2. To verify the hypothesis, we utilized Fluorescence cross-correlation spectroscopy (FCCS) and Co-immunoprecipitation (Co-IP) to prove the existence of FGFR2-3 heterodimer. To explore the function of FGFR2-3 heterodimer, we made FGFR2-dominant SAS overexpressing FGFR3 to form FGFR2-3 heterodimer. With stimulation of FGF7, FGFR2-specific ligand, the effect of FGFR2-3 heterodimer on MAPK, AKT, and STAT pathway was observed by Immunofluorescence (IF) and Western blot (WB). IF showed that FGFR2-3 heterodimer will not activate MAPK pathway. WB indicated that FGFR2-3 heterodimer will not activate AKT pathway. Therefore, preliminary result demonstrated that FGFR2-3 heterodimer would interfere with signal transduction. To further figure out whether FGFR2-3 heterodimer blocks signal transduction, I made 3 different truncated-FGFR3 plasmids (FGFR3 mutants), point mutation(K508R) FGFR3, intracellular-domain-truncated FGFR3(FGFR3-∆Intra), and transmembrane-domain-truncated FGFR3(FGFR3-∆Trans). It is reported that K508R point mutation would lead to abrogation of kinase activity of FGFR3. Deletion of intracellular domain would also abolish kinase activity of FGFR3. Because of reservation of transmembrane domain on FGFR3-K508R and FGFR3-∆Intra, we speculate they would be located on membrane and form heterodimer with FGFR2 to block signal transduction. As a result, FGFR3-K508R and FGFR3-∆Intra are regarded as negative control. Some reports pointed out that FGFR3 lacking transmembrane domain would be secreted from cell, but whether FGFR3-∆Trans form heterodimer with FGFR2 to regulate signal transduction remains elusive. To investigate whether FGFR3-∆Trans acts as drug to regulate signal transduction of FGFR2, membrane/cytosol fractionation was conducted. The result showed that all FGFR3 mutants are located on membrane. We inferred that FGFR3-∆Trans could bind with other FGFRs to remain on membrane. We expected that some FGFR3 mutants may bind with FGFR2 to interfere with signal transduction. Membrane/cytosol fractionation demonstrated that all FGFR mutants are located on membrane. With the help of these FGFR3 mutants, we hope to unravel the mystery of FGFR2-3 heterodimer. With the help of these FGFR3 mutants, we hope to unravel the effect of FGFR2-3 heterodimer on different pathways and find out the therapeutic strategies for HNSCC or FGFR2-associated diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:11:28Z (GMT). No. of bitstreams: 1 U0001-1708202017183100.pdf: 4852057 bytes, checksum: e628008f5b01714919f9c482f92733bd (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 誌謝 i 中文摘要 ii Abstract iv 目錄 vii 圖目錄 x 第一章 緒論 1 頭頸癌(Head and neck squamous cell carcinoma, HNSCC)概論與流行病學 1 頭頸癌進程與臨床治療 1 纖維母細胞生長因子受器(Fibroblast growth factor receptors, FGFRs)表現量在頭頸癌中有高度異常的現象 2 纖維母細胞生長因子受器的構型與生理功能 2 纖維母細胞生長因子(Fibroblast growth factors, FGFs)活化FGFRs 3 纖維母細胞生長因子受器的異型二聚體(Heterodimers)的功能仍為未知 4 第二章 研究動機 6 第三章 材料與方法 9 細胞培養 9 質體(Plasmid)建立 9 轉染(Transient Transfection) 10 病毒製備(Package)與病毒感染(Infection) 10 西方墨點法(Western Blot, WB) 11 膜質分離(Membrane/cytosol fractionation) 13 免疫沉澱法(Immunoprecipitation, IP) 14 免疫共沉澱法(Co-Immunoprecipitation, Co-IP) 14 免疫螢光染色(Immunofluorescence Staining, IF) 15 IF螢光強度定量 16 藥品表 16 第四章 結果 17 I. 免疫螢光染色與分析的平台建立 17 1. 建立免疫螢光染色的平台 17 2. 過度表達FGFR3來與內生性FGFR2形成FGFR2-3 heterodimer 18 3. Image J分析pERK Immunofluorescence的方法 20 II. FGF的平台建立 21 1. FGF1活化的FGFR3 homodimer會干擾FGFR2-3 heterodimer的分析 21 2. FGF7能專一性活化FGFR2,避免活化FGFR3 homodimer 22 3. FGF7能提升EGFR抑制劑所降低的pERK level 23 III. FGFR2-3 heterodimer的功能探索 24 1. FGFR2-3 heterodimer不會啟動MAPK pathway 24 2. FGFR2-3 heterodimer能啟動AKT pathway 24 3. FGFR2-3 heterodimer不會啟動AKT pathway 25 4. FGFR2與FGFR3結合形成FGFR2-3 heterodimer 27 5. 以FGFR3 mutants驗證FGFR2-3 heterodimer功能 28 6. FGFR3-∆Trans會被分泌到細胞外 29 7. FGFR3與所有的FGFR3 mutants皆存在於膜上 30 8. FGFR2-3 heterodimer對下游pathway的功能仍待驗證 32 第五章 討論 34 FGF7是否能促使FGFR2-3 heterodimer形成 34 FGFR2-3 heterodimer的量稀少 34 FGFR2-3 heterodimer、FGFR2 3 homodimer的比例 35 FGFR2-3 heterodimer於pEKR pAKT的結果差異 36 缺乏Transmembrane domain的FGFR3-∆Trans位於膜上 36 其他model的可能性 37 FGFR2-3 heterodimer是否會磷酸化 37 未來方向 38 第六章 參考文獻 39 第七章 質體地圖(Plasmid map) 43 | |
dc.language.iso | zh-TW | |
dc.title | 纖維母細胞生長因子受器第二型-第三型異型二聚體在頭頸癌上的重要性 | zh_TW |
dc.title | FGFR2-FGFR3 heterodimer:functional significance in head and neck cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 涂熊林(Hsiung-Lin Tu) | |
dc.contributor.oralexamcommittee | 張玉芳(Yu-Fong Chang),蔡金吾(Jin-Wu Tsai),李宜靜(Yi-Ching Lee) | |
dc.subject.keyword | 頭頸癌,FGFR2,FGFR3,細胞遷移,異型二聚體, | zh_TW |
dc.subject.keyword | Head and neck cancer,FGFR2,FGFR3,Cell migration,Heterodimer, | en |
dc.relation.page | 47 | |
dc.identifier.doi | 10.6342/NTU202003818 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1708202017183100.pdf 目前未授權公開取用 | 4.74 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。